An experimental drug for the heart of the Swiss company has to show more Novatis of international scientists and health experts acclaim received excellent results in the effective treatment of patients with heart disease and cardiovascular problems.
According to the results of a funded by drugmakers Novartis experimental drug study have demonstrated the effectiveness of the suppression in the treatment of heart patients to reduce the risk of hospitalization and death from cardiovascular disease by 20 percent.
Health experts and doctors said the drug from Novartis, which still has no name, and by his code name known LCZ696 is a breakthrough in the field of medical science. This drug is rare among effective treatments that soon benefited the face of heart treatment could change more than half of the six million of heart disease in the United States affected people and 24 million people worldwide.
"It's a new day for the patient. Was at least a decade since we had a breakthrough of this magnitude," said Dr. Clyde Yancy, chief of cardiology at Northwestern University in Chicago.
Yancy, former president of the American Heart Association does not participate in the study.
Dr. Milton Packer, the lead author of the study, praised the impressive results and said: ". I think that when doctors see they find attractive data, and what we see is a paradigm shift"
Dr. Packer is a professor of clinical sciences at the University of Texas Southwestern Medical Center in Dallas.
Novartis, a study of 27 months, and involved almost 8,500 people in 47 countries suffer from health ailments. It was the greatest experience ever in the field of heart medicine.
Study, researchers found that Novartis drug reduces the risk of death from heart disease by 20 percent, in contrast to the success rate of 16 percent more drugs. The rate of hospitalization for heart failure also found reduced by an impressive 21 percent.
"We are very excited," Packer said, adding :. "The benefit has exceeded our initial expectations"
The results of the clinical trial were presented at the European Society of Cardiology Congress in Barcelona, Spain on Saturday. And clinical research and its findings were published online in the New England Journal of Medicine.
The drug manufacturers will be submitted later this year for approval of the drug in the United States. Novartis will seek green signal from Europe to the drug in the first quarter of 2015, so experts say the drug would be effective on the market later this year.
As a patented drug, Novartis is expected to offer the heart means high prices.